Cross-sectional survey
| . | Replies . | Percentages . |
|---|---|---|
| Do you have a BPDCN immunophenotypic panel (CD4-CD56-CD123-BDCA2/CD303) that you use on a regular basis? | ✓ Yes ✓ No ✓ Only in selected cases | 33 17 50 |
| Your immunophenotypic panel includes markers that exclude BPDCN, such as: CD3, CD19, myeloperoxidase, CD11c, CD14, CD64? | ✓ Yes ✓ No | 0 100 |
| Does your histochemical panel include CD4, CD56, CD123, BDCA2, TCL1, or excludes: MPO, CD3, CD20 o CD19, CD163, Lysozyma? | ✓ Yes ✓ No | 57 43 |
| Do you routinely perform CD123 in acute myeloid leukemia at diagnosis? | ✓ Yes ✓ No | 59 41 |
| Do you routinely perform a cerebral fluid exam at diagnosis? | ✓ Yes ✓ No | 70 30 |
| Do you use a different therapeutic approach between BPDCN patients with leukemic spread or without? | ✓ Yes ✓ No | 26 74 |
| What type of chemotherapy do you use? AML-oriented, ALL-oriented or NHL-oriented? | ✓ AML-like ✓ ALL-like ✓ NHL-like | 39 44 17 |
| . | Replies . | Percentages . |
|---|---|---|
| Do you have a BPDCN immunophenotypic panel (CD4-CD56-CD123-BDCA2/CD303) that you use on a regular basis? | ✓ Yes ✓ No ✓ Only in selected cases | 33 17 50 |
| Your immunophenotypic panel includes markers that exclude BPDCN, such as: CD3, CD19, myeloperoxidase, CD11c, CD14, CD64? | ✓ Yes ✓ No | 0 100 |
| Does your histochemical panel include CD4, CD56, CD123, BDCA2, TCL1, or excludes: MPO, CD3, CD20 o CD19, CD163, Lysozyma? | ✓ Yes ✓ No | 57 43 |
| Do you routinely perform CD123 in acute myeloid leukemia at diagnosis? | ✓ Yes ✓ No | 59 41 |
| Do you routinely perform a cerebral fluid exam at diagnosis? | ✓ Yes ✓ No | 70 30 |
| Do you use a different therapeutic approach between BPDCN patients with leukemic spread or without? | ✓ Yes ✓ No | 26 74 |
| What type of chemotherapy do you use? AML-oriented, ALL-oriented or NHL-oriented? | ✓ AML-like ✓ ALL-like ✓ NHL-like | 39 44 17 |
NHL, non-Hodgkin lymphoma.